Research progress of gammadelta T cell-based immunotherapy / 浙江大学学报·医学版
Journal of Zhejiang University. Medical sciences
;
(6): 424-429, 2010.
Article
in Chinese
| WPRIM
| ID: wpr-319882
ABSTRACT
GammadeltaT cells are considered as linkage between innate and adaptive immune response, which recognize specific antigen without MHC-restriction. Vgamma9Vdelta2T cells, isolated from peripheral blood and tumor tissue, can be activated by non-peptide phosphoantigen through binding to its gammadeltaTCR and proliferate under IL-2 stimulation. It has been shown that Vgamma9Vdelta2T cells possess anticancer activity against several types of tumor in vitro, as well as inhibit the growth of lymphoma, breast cancer and malignant melanoma in vivo. The phase I clinical trial of the application of Vgamma9Vdelta2T cells in treatment of lung cancer, renal cancer and prostate cancer demonstrated promising results. This review summarizes the recent advances in antigen recognition and activation of gammadeltaT cells, and the gammadeltaT cell-based immunotherapy for cancer treatment.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Therapeutics
/
Immunotherapy, Adoptive
/
T-Lymphocyte Subsets
/
Receptors, Antigen, T-Cell, gamma-delta
/
Allergy and Immunology
/
Immunotherapy
/
Methods
/
Neoplasms
Limits:
Humans
Language:
Chinese
Journal:
Journal of Zhejiang University. Medical sciences
Year:
2010
Type:
Article
Similar
MEDLINE
...
LILACS
LIS